TrustCore Financial Services’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$192K Hold
2,090
0.02% 276
2022
Q3
$252K Hold
2,090
0.02% 236
2022
Q2
$161K Hold
2,090
0.02% 280
2022
Q1
$325K Buy
2,090
+675
+48% +$16.3K 0.03% 218
2021
Q4
$341K Hold
1,415
0.04% 197
2021
Q3
$608K Hold
1,415
0.06% 151
2021
Q2
$773K Hold
1,415
0.08% 127
2021
Q1
$553K Hold
1,415
0.06% 156
2020
Q4
$606K Hold
1,415
0.08% 136
2020
Q3
$1.2M Hold
1,415
0.18% 69
2020
Q2
$1.17M Hold
1,415
0.2% 67
2020
Q1
$525K Hold
1,415
0.12% 111
2019
Q4
$539K Buy
1,415
+1,394
+6,638% +$130K 0.1% 126
2019
Q3
$36K Hold
21
0.01% 425
2019
Q2
$34K Buy
+21
New +$5.94K 0.01% 425

Other funds holding KRSA

TrustCore Financial Services's KRSA Position: Q4 2022 in Review

TrustCore Financial Services held its Korsana Biosciences, Inc. Common Stock (KRSA) position steady in Q4 2022 at 2,090 shares worth $192K. The position accounts for 0.02% of the portfolio, ranked #276.

TrustCore Financial Services first reported a position in KRSA in Q2 2019 and has held it in 15 quarters since. The position peaked at $1.2M in Q3 2020. 33 funds tracked by Wall St. Rank hold KRSA as of Q4 2022.

  • TrustCore Financial Services held 2,090 shares of Korsana Biosciences, Inc. Common Stock worth $192K as of Q4 2022.
  • TrustCore Financial Services left its Korsana Biosciences, Inc. Common Stock share count unchanged in Q4 2022.
  • Korsana Biosciences, Inc. Common Stock made up 0.02% of TrustCore Financial Services's portfolio in Q4 2022, its #276 holding.
  • TrustCore Financial Services first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and has held it in 15 quarters since.
  • TrustCore Financial Services's Korsana Biosciences, Inc. Common Stock position peaked at $1.2M in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.